Lataa...
Pertuzumab in the treatment of HER2-positive breast cancer: an evidence-based review of its safety, efficacy, and place in therapy
Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is a distinct subset of breast cancer that results from overexpression of HER2 protein. Pertuzumab—a recombinant humanized monoclonal antibody that binds to the extracellular dimerization domain II of HER2—was recently approved f...
Tallennettuna:
| Julkaisussa: | Core Evid |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Dove
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6827570/ https://ncbi.nlm.nih.gov/pubmed/31802990 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CE.S217848 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|